Skip to main content
Top
Published in: Supportive Care in Cancer 4/2016

01-04-2016 | Original Article

Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life

Authors: Edward Chow, Keyue Ding, Wendy R. Parulekar, Rebecca K. S. Wong, Yvette M. van der Linden, Daniel Roos, William F. Hartsell, Peter Hoskin, Jackson S. Y. Wu, Abdenour Nabid, Francisca Ong, Geertjan van Tienhoven, Scott Babington, William F. Demas, Carolyn F. Wilson, Michael Brundage, Liting Zhu, Ralph M. Meyer

Published in: Supportive Care in Cancer | Issue 4/2016

Login to get access

Abstract

Purpose

The objective of our study was to determine the optimal cut points for classification of pain scores as mild, moderate, and severe based on interference with function and quality of life (QOL).

Methods

We evaluated 822 patients who completed the Brief Pain Inventory (BPI) and/or the European Organization for Research and Treatment of Cancer (EORTC) QOL Questionnaire Core 30 (QLQ-C30) prior to receiving repeat radiation therapy for previously irradiated painful bone metastases. Optimal cut points for mild, moderate, and severe pain were determined by the MANOVA that yielded the largest F ratio for the between category effect on the seven interference items of BPI and the six functional domains of QOL (physical, role, emotional, cognitive, social functioning, and global QOL) as indicated by Pillai’s Trace, Wilk’s λ, and Hostelling’s Trace F statistics.

Results

For BPI and for QOL domains separately, the two largest F ratios for Wilk’s λ, Pillai’s Trace, and Hotelling’s Trace F statistics were from the cut points 4, 8 and 6, 8. When combining both, the optimal cut points were 4, 8 with 1–4 (mild), 5–8 (moderate), and 9–10 (severe). With this classification, the mean scores of all the seven interference items in BPI and the six functional domains were all highly statistically different. Patients with severe pain survived significantly shorter than those with mild and moderate pain (p < 0.0001).

Conclusion

Our analysis supports the classification of pain scores as follows: 1–4 as mild pain, 5–8 as moderate pain, and 9–10 as severe pain. This may facilitate conduct of future clinical trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cleeland CS (1984) The impact of pain on the patient with cancer. Cancer 45(11 Suppl):2635–2641CrossRef Cleeland CS (1984) The impact of pain on the patient with cancer. Cancer 45(11 Suppl):2635–2641CrossRef
2.
go back to reference Daut RL, Cleeland CS, Flanery RC (1983) Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17(2):197–210CrossRefPubMed Daut RL, Cleeland CS, Flanery RC (1983) Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17(2):197–210CrossRefPubMed
3.
go back to reference Williamson A (2005) Pain: a review of three commonly used pain rating scales. J Clin Nurs 14:798–804CrossRefPubMed Williamson A (2005) Pain: a review of three commonly used pain rating scales. J Clin Nurs 14:798–804CrossRefPubMed
5.
go back to reference Society AP (2005) Guidelines for the management of cancer pain in adults and children. Glenview, IL. American Pain Society Society AP (2005) Guidelines for the management of cancer pain in adults and children. Glenview, IL. American Pain Society
8.
go back to reference Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277–284CrossRefPubMed Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277–284CrossRefPubMed
9.
go back to reference Li K, Harris K, Hadi S, Chow E (2007) What should be the optimal cut points for mild, moderate, and severe pain? Journal of Palliative Medicine 10(6):1338–1346CrossRefPubMed Li K, Harris K, Hadi S, Chow E (2007) What should be the optimal cut points for mild, moderate, and severe pain? Journal of Palliative Medicine 10(6):1338–1346CrossRefPubMed
10.
go back to reference Paul SM, Zaelman DC, Smith M, Miaskowski C (2005) Categorizing the severity of cancer pain: further exploration of the establishments of cut points. Pain 1123:37–44CrossRef Paul SM, Zaelman DC, Smith M, Miaskowski C (2005) Categorizing the severity of cancer pain: further exploration of the establishments of cut points. Pain 1123:37–44CrossRef
11.
go back to reference Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, et al (2014) Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 15(2):164–171CrossRefPubMed Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, et al (2014) Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 15(2):164–171CrossRefPubMed
12.
go back to reference Chow E, Meyer RM, Chen BE, van der Linden YM, Roos D, Hartsell WF, et al (2014) Impact of reirradiation of painful osseous metastases on quality of life and function: a secondary analysis of the NCIC CTG SC.20 randomized trial. J Clin Oncol 32(34):3867–3873PubMedCentralCrossRefPubMed Chow E, Meyer RM, Chen BE, van der Linden YM, Roos D, Hartsell WF, et al (2014) Impact of reirradiation of painful osseous metastases on quality of life and function: a secondary analysis of the NCIC CTG SC.20 randomized trial. J Clin Oncol 32(34):3867–3873PubMedCentralCrossRefPubMed
13.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMed
14.
go back to reference Marascuilo LA, Levin JR (1983) Multivariate statistics in the social sciences: a researcher’s guide. Brooks/Cole Publ, Monterey, CA Marascuilo LA, Levin JR (1983) Multivariate statistics in the social sciences: a researcher’s guide. Brooks/Cole Publ, Monterey, CA
15.
go back to reference Rosner B (2005) Fundamentals of biostatistics. 6th edn, Duxbury Press Rosner B (2005) Fundamentals of biostatistics. 6th edn, Duxbury Press
16.
go back to reference Cox DR (1972) Regression models and lifetables. J R Stat Soc [B] 34:187–220 Cox DR (1972) Regression models and lifetables. J R Stat Soc [B] 34:187–220
17.
go back to reference Wang XS, Cleeland CS, Mendoza TR, Engstrom MC, Liu S, Xu G, et al (1999) The effects of pain severity on health-related quality of life. Cancer 86(9):1848–1855CrossRefPubMed Wang XS, Cleeland CS, Mendoza TR, Engstrom MC, Liu S, Xu G, et al (1999) The effects of pain severity on health-related quality of life. Cancer 86(9):1848–1855CrossRefPubMed
18.
go back to reference Chow E, Doyle M, Li K, Bradley N, Harris K, Hruby G, et al (2006) Mild, moderate or severe pain categorized by patients with bone metastases. J Palliat Med 9:850–854CrossRefPubMed Chow E, Doyle M, Li K, Bradley N, Harris K, Hruby G, et al (2006) Mild, moderate or severe pain categorized by patients with bone metastases. J Palliat Med 9:850–854CrossRefPubMed
19.
go back to reference Jensen MP, Smith DG, Ehde DM, Robinsin LR (2001) Pain site and the effects of amputation pain: further clarification of the meaning of mild, moderate and severe pain. Pain 91:317–322CrossRefPubMed Jensen MP, Smith DG, Ehde DM, Robinsin LR (2001) Pain site and the effects of amputation pain: further clarification of the meaning of mild, moderate and severe pain. Pain 91:317–322CrossRefPubMed
Metadata
Title
Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life
Authors
Edward Chow
Keyue Ding
Wendy R. Parulekar
Rebecca K. S. Wong
Yvette M. van der Linden
Daniel Roos
William F. Hartsell
Peter Hoskin
Jackson S. Y. Wu
Abdenour Nabid
Francisca Ong
Geertjan van Tienhoven
Scott Babington
William F. Demas
Carolyn F. Wilson
Michael Brundage
Liting Zhu
Ralph M. Meyer
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2957-5

Other articles of this Issue 4/2016

Supportive Care in Cancer 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine